News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY)'s Experimental Drug Helps Body Fight Advanced Melanoma


3/4/2014 7:40:20 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

A drug that uses the body's own immune system to kill cancer cells has produced lasting remissions - some as long as two years - in patients with melanoma that had spread to other parts of the body, according to data published on Monday. Follow-up from an early-stage, 107-patient trial of the drug, Bristol-Myers Squibb's nivolumab, found that a year after treatment, 62 percent of patients were alive. After two years, 43 percent were alive. Patients with advanced melanoma, the deadliest form of skin cancer, have a median life expectancy of around a year, said Dr. F. Stephen Hodi, director of the Melanoma Treatment Center at Boston's Dana-Farber Cancer Institute and one of the study's senior authors.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at MedicalXpress
Read at EurekAlert!


comments powered by Disqus
   
Melanoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES